Ertaczo

(arasertaconazole nitrate)

Phase 2Small molecule

Alnylam Pharmaceuticals

Ertaczo is one of 19 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Vulvovaginal CandidiasisActive, not recruiting

Vulvovaginal CandidiasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Vulvovaginal Candidiasis

#DrugCompanyPhaseTrials

Lotrimin

Bayer

Approved

4 2

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

15 3

Nizoral

Terazol 3

2 5

Canesten

AAVVA Pharmaceuticals Ltd.

Approved

1 6

Peridex

MMedline Industries

Phase 2

1 7

Vaccine

Pfizer

Phase 2

1 8

Brexafemme

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Boric Acid

MMansoura University

Phase 3

1 10

Butoconazole Nitrate

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vulvovaginal Candidiasis1 trial

Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment

Completed·FFerrer Internacional S.A.·Phase 2·NCT01144286·229 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 10, 2003

ERTACZO

NDA NDA021385

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for arasertaconazole nitrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — arasertaconazole nitrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for arasertaconazole nitrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021385). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Alnylam Pharmaceuticals

Ertaczo

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vulvovaginal Candidiasis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News